• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人类过氧化物酶体增殖物激活受体(PPAR)亚型PPARγ2与PPARγ1的鉴定、特性及组织分布,以及视黄酸X受体激动剂和拮抗剂对其的激活作用

Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists.

作者信息

Mukherjee R, Jow L, Croston G E, Paterniti J R

机构信息

Department of Cardiovascular Research, Ligand Pharmaceuticals, Inc., San Diego, California 92121, USA.

出版信息

J Biol Chem. 1997 Mar 21;272(12):8071-6. doi: 10.1074/jbc.272.12.8071.

DOI:10.1074/jbc.272.12.8071
PMID:9065481
Abstract

We describe the cloning, characterization, and tissue distribution of the two human peroxisome proliferator activated receptor isoforms hPPARgamma2 and hPPARgamma1. In cotransfection assays the two isoforms were activated to approximately the same extent by known PPARgamma activators. Human PPARgamma binds to DNA as a heterodimer with the retinoid X receptor (RXR). This heterodimer was activated by both RXR agonists and antagonists and the addition of PPARgamma ligands with retinoids resulted in greater than additive activation. Such heterodimer-selective modulators may have a role in the treatment of PPARgamma/RXR-modulated diseases like diabetes. Northern blot analysis indicated the presence of PPARgamma in skeletal muscle, and a sensitive RNase protection assay confirmed the presence of only PPARgamma1 in muscle that was not solely due to fat contamination. However, both PPARgamma1 and PPARgamma2 RNA were detected in fat, and the ratio of PPARgamma1 to PPARgamma2 RNA varied in different individuals. The presence of tissue-specific distribution of isoforms and the variable ratio of PPARgamma1 to PPARgamma2 raised the possibility that isoform expression may be modulated in disease states like non-insulin-dependent diabetes mellitus. Interestingly, a third protected band was detected with fat RNA indicating the possible existence of a third human PPARgamma isoform.

摘要

我们描述了两种人类过氧化物酶体增殖物激活受体亚型hPPARγ2和hPPARγ1的克隆、特性及组织分布。在共转染实验中,这两种亚型被已知的PPARγ激活剂激活的程度大致相同。人类PPARγ与视黄酸X受体(RXR)以异二聚体形式结合于DNA。这种异二聚体被RXR激动剂和拮抗剂激活,并且PPARγ配体与类视黄醇的添加导致激活作用大于相加效应。这种异二聚体选择性调节剂可能在治疗如糖尿病等PPARγ/RXR调节的疾病中发挥作用。Northern印迹分析表明骨骼肌中存在PPARγ,一种灵敏的核糖核酸酶保护试验证实肌肉中仅存在PPARγ1,这并非仅仅由于脂肪污染所致。然而,在脂肪中同时检测到PPARγ1和PPARγ2的RNA,并且PPARγ1与PPARγ2 RNA的比例在不同个体中有所变化。亚型的组织特异性分布以及PPARγ1与PPARγ2的可变比例增加了在非胰岛素依赖型糖尿病等疾病状态下亚型表达可能被调节的可能性。有趣的是,用脂肪RNA检测到第三条受保护条带,表明可能存在第三种人类PPARγ亚型。

相似文献

1
Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists.人类过氧化物酶体增殖物激活受体(PPAR)亚型PPARγ2与PPARγ1的鉴定、特性及组织分布,以及视黄酸X受体激动剂和拮抗剂对其的激活作用
J Biol Chem. 1997 Mar 21;272(12):8071-6. doi: 10.1074/jbc.272.12.8071.
2
Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer.过氧化物酶体增殖物激活受体γ与视黄酸X受体异二聚体对化学预防谷胱甘肽S-转移酶基因中PPAR反应性增强子模块的反式激活作用。
Cancer Res. 2004 May 15;64(10):3701-13. doi: 10.1158/0008-5472.CAN-03-3924.
3
T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities.T0070907是过氧化物酶体增殖物激活受体γ的选择性配体,具有生化和细胞活性拮抗剂的作用。
J Biol Chem. 2002 May 31;277(22):19649-57. doi: 10.1074/jbc.M200743200. Epub 2002 Mar 4.
4
Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists.类视黄醇X受体激动剂使糖尿病和肥胖小鼠对胰岛素敏感。
Nature. 1997 Mar 27;386(6623):407-10. doi: 10.1038/386407a0.
5
Relationships of PPARgamma and PPARgamma2 mRNA levels to obesity, diabetes and hyperinsulinaemia in rhesus monkeys.恒河猴中PPARγ和PPARγ2 mRNA水平与肥胖、糖尿病及高胰岛素血症的关系
Int J Obes Relat Metab Disord. 1998 Oct;22(10):1000-10. doi: 10.1038/sj.ijo.0800718.
6
A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation.一种在天然启动子处分析核受体功能的新方法:使用分支DNA信使核糖核酸定量检测过氧化物酶体增殖物激活受体γ激动剂对aP2基因表达的作用。
Mol Endocrinol. 1999 Mar;13(3):410-7. doi: 10.1210/mend.13.3.0246.
7
Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin.过氧化物酶体增殖物激活受体γ(PPARγ)N端的非配体依赖性激活结构域。PPARγ1和-2亚型的差异活性及胰岛素的影响。
J Biol Chem. 1997 Aug 8;272(32):20230-5. doi: 10.1074/jbc.272.32.20230.
8
Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies.通过视黄酸X受体(RXR)/过氧化物酶体增殖物激活受体γ(PPARγ)异二聚体激活剂减轻结肠炎症。新治疗策略的基础。
J Exp Med. 2001 Apr 2;193(7):827-38. doi: 10.1084/jem.193.7.827.
9
Regional differences in the response of human pre-adipocytes to PPARgamma and RXRalpha agonists.人类前脂肪细胞对PPARγ和RXRα激动剂反应的区域差异。
Diabetes. 2002 Mar;51(3):718-23. doi: 10.2337/diabetes.51.3.718.
10
Limited cooperation between peroxisome proliferator-activated receptors and retinoid X receptor agonists in sebocyte growth and development.过氧化物酶体增殖物激活受体与视黄酸X受体激动剂在皮脂细胞生长和发育中的合作有限。
Mol Genet Metab. 2001 Nov;74(3):362-9. doi: 10.1006/mgme.2001.3242.

引用本文的文献

1
Peroxisome Proliferator-Activated Receptors (PPARs) May Mediate the Neuroactive Effects of Probiotic Metabolites: An In Silico Approach.过氧化物酶体增殖物激活受体(PPARs)可能介导益生菌代谢产物的神经活性作用:一种计算机模拟方法
Int J Mol Sci. 2025 May 9;26(10):4507. doi: 10.3390/ijms26104507.
2
The Tumor Suppressor Par-4 Regulates Adipogenesis by Transcriptional Repression of PPARγ.肿瘤抑制因子 Par-4 通过转录抑制 PPARγ 来调节脂肪生成。
Cells. 2024 Sep 5;13(17):1495. doi: 10.3390/cells13171495.
3
The Peroxisome Proliferator-Activated Receptors of Ray-Finned Fish: Unique Structures, Elusive Functions.
《硬骨鱼类过氧化物酶体增殖物激活受体:独特的结构,难以捉摸的功能》。
Biomolecules. 2024 May 29;14(6):634. doi: 10.3390/biom14060634.
4
Harnessing peroxisome proliferator-activated receptor γ agonists to induce Heme Oxygenase-1: a promising approach for pulmonary inflammatory disorders.利用过氧化物酶体增殖物激活受体 γ 激动剂诱导血红素加氧酶-1:一种治疗肺部炎症性疾病的有前途的方法。
Cell Commun Signal. 2024 Feb 15;22(1):125. doi: 10.1186/s12964-024-01501-4.
5
Integrated bioinformatics and network pharmacology to explore the therapeutic target and molecular mechanisms of Bailing capsule on polycystic ovary syndrome.综合生物信息学和网络药理学探讨百灵胶囊治疗多囊卵巢综合征的作用靶点及分子机制。
BMC Complement Med Ther. 2023 Dec 15;23(1):458. doi: 10.1186/s12906-023-04280-6.
6
Integrated investigation and experimental validation of PPARG as an oncogenic driver: implications for prognostic assessment and therapeutic targeting in hepatocellular carcinoma.PPARG作为致癌驱动因子的综合研究与实验验证:对肝细胞癌预后评估和治疗靶点的意义
Front Pharmacol. 2023 Nov 15;14:1298341. doi: 10.3389/fphar.2023.1298341. eCollection 2023.
7
D-Chiro-Inositol and Myo-Inositol Induce WAT/BAT Trans-Differentiation in Two Different Human Adipocyte Models (SGBS and LiSa-2).D-手性肌醇和肌醇诱导两种不同的人脂肪细胞模型(SGBS 和 LiSa-2)的白色脂肪/棕色脂肪转分化。
Int J Mol Sci. 2023 Apr 18;24(8):7421. doi: 10.3390/ijms24087421.
8
Peptide Helix-Y as Potential Effector for Peroxisome Proliferator-Activated Receptors.肽螺旋-Y作为过氧化物酶体增殖物激活受体的潜在效应物
PPAR Res. 2023 Apr 15;2023:8047378. doi: 10.1155/2023/8047378. eCollection 2023.
9
Integrated Whole-Exome and Transcriptome Sequencing Indicated Dysregulation of Cholesterol Metabolism in Eyelid Sebaceous Gland Carcinoma.全外显子组和转录组测序表明胆固醇代谢失调与眼睑皮脂腺癌有关。
Transl Vis Sci Technol. 2023 Feb 1;12(2):4. doi: 10.1167/tvst.12.2.4.
10
Profound Modification of Fatty Acid Profile and Endocannabinoid-Related Mediators in PPARα Agonist Fenofibrate-Treated Mice.PPARα 激动剂非诺贝特处理的小鼠中脂肪酸谱和内源性大麻素相关介质的深刻修饰。
Int J Mol Sci. 2022 Dec 31;24(1):709. doi: 10.3390/ijms24010709.